Drug Profile
BI 1323495
Alternative Names: BI-1323495Latest Information Update: 28 Apr 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Antibronchitics; Bronchodilators
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bronchiectasis; Chronic obstructive pulmonary disease
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Bronchiectasis(Treatment-experienced) in Germany (PO, Tablet)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Bronchiectasis(Treatment-experienced) in United Kingdom (PO, Tablet)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Japan (PO, Tablet)